1. Home
  2. ASST vs ANNX Comparison

ASST vs ANNX Comparison

Compare ASST & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asset Entities Inc. Class B

ASST

Asset Entities Inc. Class B

HOLD

Current Price

$10.63

Market Cap

685.1M

Sector

Technology

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.86

Market Cap

730.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASST
ANNX
Founded
2020
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
685.1M
730.4M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
ASST
ANNX
Price
$10.63
$5.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$16.00
$16.50
AVG Volume (30 Days)
3.0M
2.4M
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
82.56
N/A
EPS
N/A
N/A
Revenue
$633,489.00
N/A
Revenue This Year
$294.91
N/A
Revenue Next Year
$12.16
$22,605.10
P/E Ratio
N/A
N/A
Revenue Growth
128.67
N/A
52 Week Low
$0.47
$1.40
52 Week High
$13.40
$7.18

Technical Indicators

Market Signals
Indicator
ASST
ANNX
Relative Strength Index (RSI) 58.05 55.27
Support Level $0.74 $4.79
Resistance Level $11.27 $6.50
Average True Range (ATR) 0.78 0.44
MACD -0.14 0.09
Stochastic Oscillator 89.47 66.67

Price Performance

Historical Comparison
ASST
ANNX

About ASST Asset Entities Inc. Class B

Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: